14505-28-3

Upstream product

• 105-56-6 ethyl 2-cyanoacetate 
• 122-00-9 para-methylacetophenone 

Downstream Products

• 92579-73-2 2,3-dicyano-3-p-tolyl-butyric acid ethyl ester 
• 117489-20-0 2-Oxo-1,4,6-triphenyl-1,2,5,6-tetrahydro-pyridine-3-carbonitrile 
• 39724-76-0 2-cyano-3-(p-tolyl)but-2-enoic acid 
• 58245-31-1 Aethyl-2,4-di-p-tolyl-5-cyano-5-aethoxycarbonyl-6-imino-4-methyl-1-cyclohexencarboxylat 
• 243117-78-4 2-cyano-5-[1,3]dioxolan-2-yl-3-methyl-3-p-tolyl-pentanoic acid ethyl ester 
• 113860-93-8 4-(3-ethyl-3H-benzothiazol-2-ylidene)-2-cyano-3-p-tolyl-crotonic acid ethyl ester 
• 58299-80-2 5-Methyl-3,5-di-p-tolyl-cyclohex-2-enone 
• 86945-26-8 1,2-dicyano-2-(4-methylphenyl)-propane 
• 22836-90-4 α-Methyl-α-(p-tolyl)-bernsteinsaeure 
• 374104-63-9 4-chloro-5-(p-tolyl)thieno[2,3-d]pyrimidine 
• 15854-08-7 ethyl 2-amino-4-(4-methylphenyl)thiophene-3-carboxylate 
• 39027-57-1 3-(4-methylphenyl)butanoic acid 
• 518013-95-1 5-[1,3]dioxolan-2-yl-3-methyl-3-p-tolyl-pentanoic acid methyl ester 
• 100717-83-7 2-cyano-3-p-tolyl-butyric acid ethyl ester 

Relevant academic research and scientific papers

Novel bis-(3-cyano-2-pyridones) derivatives: synthesis and fluorescent properties

Abstract: Novel substituted bis-(3-cyano-2-pyridone) derivatives were prepared via a powerful method using enaminonitriles push–pull dienes as key building blocks. The synthesis was performed in three steps from easily accessible starting materials in goo

Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.

THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS

The present invention provides thienopyrimidine compounds which are potasium channels inhibitors. Pharmaceutical compositions comprising the compounds and their use in the treatment of arrhythmia are also provided.